DelveInsight’s, “Refractory Multiple Myeloma Pipeline Insight, 2023,” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Refractory Multiple Myeloma pipeline landscape. It covers the Refractory Multiple Myeloma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Refractory Multiple Myeloma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Refractory Multiple Myeloma Pipeline Report
- DelveInsight’s Refractory Multiple Myeloma pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Refractory Multiple Myeloma treatment.
- The leading companies working in the Refractory Multiple Myeloma Market include NexImmune, Amgen, AbbVie, Allogene Therapeutics, Precision Biosciences, Takeda Oncology, ORIC Pharmaceuticals, Ionis Pharmaceuticals, Cellectis S.A., YZY Biopharma, Janssen Research & Development, Bristol Myers Squibb, Lava Therapeutics, Prelude Therapeutics, and others.
- Promising Refractory Multiple Myeloma Pipeline Therapies in the various stages of development include Venetoclax, Dexamethasone, Carfilzomib, Elotuzumab, Thalidomide, Cyclophosphamide, and others.
- October 2023: Regeneron Pharmaceuticals announced a study of Phase 3 clinical trials for Linvoseltamab and Elotuzumab. The study is researching an experimental drug called linvoseltamab, also called REGN5458. This study is focused on participants who have multiple myeloma that has returned or needs to be treated again after one to four prior treatments and have standard cancer treatment options available to them. The aim of the study is to see how safe and effective linvoseltamab is compared to a combination of three cancer drugs: elotuzumab, pomalidomide and dexamethasone (called "EPd" in this form), one of these standard treatment options. Half of the participants in this study will get linvoseltamab, and the other half will get EPd.
- October 2023: AbbVie announced a study of Phase 1 clinical trials for ABBV-453, Dexamethasone, Daratumumab, and Lenalidomide. In Part 1 and the Japan Cohort, Participants will receive oral ABBV-453 tablets once daily (QD) in 28-day cycles. In Part 2, Arm 1, participants will receive continuous doses of oral ABBV-453 tablets QD in combination with oral dexamethasone tablets once weekly in 28-day cycles. In Part 2, Arm 2, participants will receive continuous doses of oral ABBV-453 tablets QD in combination with subcutaneous injections of daratumumab every 1 to 4 weeks and oral dexamethasone tablets once weekly in, 28-day cycles. In Part 2, Arm 3, participants will receive continuous doses of oral ABBV-453 tablets QD in combination with subcutaneous injections of daratumumab every 1 to 4 weeks, oral lenalidomide capsules QD on Days 1-21, and oral dexamethasone tablets once weekly, in 28-day cycles.
Request a sample and discover the recent advances in Refractory Multiple Myeloma Treatment Drugs @ Refractory Multiple Myeloma Pipeline Report
In the Refractory Multiple Myeloma Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Refractory Multiple Myeloma clinical trials studies, NDA approvals (if any), and product development activities comprising the technology, Refractory Multiple Myeloma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Refractory Multiple Myeloma Overview
Multiple myeloma is a cancer that starts in a type of white blood cell called a plasma cell. It’s relatively rare, making up less than 2 percent, but it’s the most common type of plasma cell tumor, according to the CDC. The survival rate of multiple myeloma has improved in recent years, but initial treatment still isn’t effective at completely getting rid of the cancer in the vast majority.
Find out more about Refractory Multiple Myeloma Therapeutics Assessment @ Refractory Multiple Myeloma Preclinical and Discovery Stage Products
Refractory Multiple Myeloma Emerging Drugs Profile
- NEXI 002: NexImmune
- AMG-701: Amgen
- ABBV 453: AbbVie
Refractory Multiple Myeloma Pipeline Therapeutics Assessment
There are approx. 80+ key companies which are developing the Refractory Multiple Myeloma therapies. The Refractory Multiple Myeloma companies which have their Refractory Multiple Myeloma drug candidates in the most advanced stage, i.e. Phase I/II include, NexImmune.
DelveInsight’s Refractory Multiple Myeloma pipeline report covers around 80+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Refractory Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
Refractory Multiple Myeloma Pipeline Products have been categorized under various Molecule types such as
- Oligonucleotide
- Peptide
- Small molecule
Learn more about the emerging Refractory Multiple Myeloma Pipeline Therapies @ Refractory Multiple Myeloma Clinical Trials Assessment
Scope of the Refractory Multiple Myeloma Pipeline Report
- Coverage- Global
- Refractory Multiple Myeloma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Refractory Multiple Myeloma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Refractory Multiple Myeloma Companies- NexImmune, Amgen, AbbVie, Allogene Therapeutics, Precision Biosciences, Takeda Oncology, ORIC Pharmaceuticals, Ionis Pharmaceuticals, Cellectis S.A., YZY Biopharma, Janssen Research & Development, Bristol Myers Squibb, Lava Therapeutics, Prelude Therapeutics, and others.
- Refractory Multiple Myeloma Pipeline Therapies- Venetoclax, Dexamethasone, Carfilzomib, Elotuzumab, Thalidomide, Cyclophosphamide, and others.
Dive deep into rich insights for new drugs for Refractory Multiple Myeloma Treatment, Visit @ Refractory Multiple Myeloma Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Refractory Multiple Myeloma: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Refractory Multiple Myeloma– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Drug name : Company name
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase I/II)
- NEXI 002: NexImmune
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- ABBV 453: AbbVie
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name : Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Refractory Multiple Myeloma Key Companies
- Refractory Multiple Myeloma Key Products
- Refractory Multiple Myeloma- Unmet Needs
- Refractory Multiple Myeloma- Market Drivers and Barriers
- Refractory Multiple Myeloma- Future Perspectives and Conclusion
- Refractory Multiple Myeloma Analyst Views
- Refractory Multiple Myeloma Key Companies
- Appendix
For further information on the Refractory Multiple Myeloma Pipeline therapeutics, reach out to Refractory Multiple Myeloma Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/refractory-multiple-myeloma-market
